Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance

Brazilian Journal of Microbiology

Volumn 38, Issue 2, 2007, Pages 183-193

  Santos Filho, Lauro ^a   Kuti, Joseph L ^b   Nicolau, David P ^b  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotic; Bacteria; Pharmacodynamics; Resistance

Indexed keywords

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 34447115722     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822007000200001     Document Type: Review

References (83)

1. Allen, G.P.; Kaatz, G.W.; Rybak, M.J. (2003). Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother., 47, 2606-2614.
2. Alvarez, C.; Cortes, J.; Arango, A.; Correa, C.; Leal, A. (2006). Antimicrobial resistance in intensive care units in Bogota, Colombia, 2001-2003. Rev. Salud Publica (Bogota), 8 (Suppl 1), 86-101.
3. Ambrose, P.G.; Grasela, D.M.; Grasela, T.H.; Passarell, J.; Mayer, H.B.; Pierce, P.F. (2001). Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother., 45, 2793-2797.
4. Anaizi, N. (1997). Once daily dosing of aminoglycosides: a consensus document. Int. J. Clin. Pharmacol. Ther., 35, 223-226.
5. Anderson, K.B.; Tan, J.S.; File, T.M. DiPersio, J.R.; Willey, B.M.; Low, D.E. (2003). Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin. Infect. Dis., 37, 376-81.
6. Andes, D.; van Ogtrop, M.L.; Peng, J.; Craig, W.A. (2002). In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother., 46, 3484-3489.
7. Andrade, S.S.; Jones, R.N.; Gales, A.C.; Sader, H.S. (2003). Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Antimicrob. Chemother., 52, 140-141.
8. Bradley, J.S.; Dudley, M.N.; Drusano, G.L. (2003). Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr. Infect. Dis. J., 22, 982-992.
9. Brueggemann, A.B.; Coffman, S.L.; Rhomberg, P.; Huynh, H.; Almer, L.; Nilius, A.; Flamm, R.; Doern, G.V. (2002). Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother., 46, 680-688.
10. Buck, C.; Bertram, N.; Ackermann, T.; Sauerbruch, T.; Derendorf, H.; Paar, W.D. (2005). Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int. J. Antimicrob. Agents, 25, 62-67.
11. Camargos, P.; Fischer, G.B.; Mocelin, H.; Dias, C.; Ruvinsky, R. (2006). Penicillin resistance and serotyping of Streptococcus pneumoniae in Latin America. Paediatr. Respir. Rev., 7, 209-214.
12. Castanheira, M.; Gales, A.C.; Mendes, R.E.; Jones, R.N.; Sader, H.S. (2004). Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin. Microbiol. Infect., 10, 645-651.
13. Cosgrove, S.E.; Carroll, K.C.; Perl, T.M. (2004). Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis., 39, 539-545.
14. Craig, W.A. (1998). Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 26, 1-10.
15. Craig, W.A.; Ebert, S.C. (1992). Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother., 36, 2577-2583.
16. Dagan, R.; Klugman, K.P.; Craig, W.A.; Baquero, F. (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother., 47, 129-140.
17. Dandekar, P.K.; Tessier, P.R.; Williams, P.; Nightingale, C.H.; Nicolau, D.P. (2003). Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother., 52, 405-411.
18. De A. Trindade, P.; Pacheco, R.L.; Costa, S.F.; Rossi, F.; Barone, A.A.; Mamizuka, E.M.; Levin, A.S. (2005). Prevalence of SCCmec type IV in nosocomial bloodstream isolates of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol., 43, 3435-3437.
19. Drusano, G.L. (2004). Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol., 2, 289-300.
20. Drusano, G.L.; Preston, S.L.; Fowler, C.; Corrado, M.; Weisinger, B.; Kahn, J. (2004). Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis., 189, 1590-1597.
21. Dudley, M.N.; Ambrose, P.G. (2000). Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol., 3, 515-521.
22. Eagle, H.; Fleischman, R.; Levy, M. (1953). "Continuous" vs. "discontinuous" therapy with penicillin: the effect of the interval between injections on therapeutic efficacy. N. Eng. J. Med., 248, 481-488.
23. Falagas, M.E.; Kasiakou, S.K.; Kofterisis, D.P.; Roditakis, G.; Samonis, G. (2006). Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis., 25, 596-599.
24. Florea, N.R.; Tessier, P.R.; Zhang, C.; Nightingale, C.H.; Nicolau, D.P. (2004). Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother., 48, 1215-1221.
25. Forrest, A.; Nix, D.E.; Ballow, C.H.; Goss, T.F.; Birmingham, M.C.; Schentag, J.J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother., 37, 1073-1081.
26. Freeman, C.D.; Nicolau, D.P.; Belliveau, P.P.; Nightingale, C.H. (1997). Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother., 39, 677-686.
27. Fritsche, T.R.; Sader, H.S.; Stilwell, M.G.; Dowzicky, M.J.; Jones, R.N. (2005). Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis., 52, 195-201.
28. Gales, A.C.; Andrade, S.S.; Sader, H.S.; Jones, R.N. (2004). Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J. Chemother., 16, 323-328.
29. Gales, A.C.; Sader, H.S.; Jones, R.N. (2002). Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis., 44, 301-311.
30. Gales, A.C.; Jones, R.N.; Sader, H.S. (2006). Global assessment of the antimicrobial activity of polymixin B against 54,731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect., 12, 315-321.
31. Gilbert, D.N.; Moellering, R.C.; Sande, M.A. (eds). (2001). The Sanford guide to antimicrobial therapy 2001, 31st ed. Hyde Park, VT: Antimicrobial Therapy, Inc.
32. Herold, M.C.; Hulten, K.G.; Palazzi, D.L.; Campbell, J.R.; Baker, C.J. (1998). Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA, 279, 593-598.
33. Johnson, D.M.; Stilwell, M.G.; Fritsche, T.R.; Jones, R.N. (2006). Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn. Microbiol. Infect. Dis., 56, 69-74.
34. Jumbe, N.; Louie, A.; Leary, R.; Liu, W.; Deziel, M.R.; Tam, V.H.; Bachhawat, R.; Freeman, C.; Kahn, J.B., Bush, K.; Dudley, M.N.; Miller, M.H.; Drusano, G.L. (2003). Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest., 112, 275-285.
35. Kashuba, A.D.M.; Bertino, J.S.; Nafziger, A.N. (1998). Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob. Agents Chemother., 42, 1842-1844.
36. Kasiakou, S.K.; Lawrence, K.R.; Choulis, N.; Falagas, M.E. (2005). Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs, 65, 2499-2511.
37. Kays, M.B.; Denys, G.A. (2001). In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. Clin. Ther., 23, 413-424.
38. Kays, M.B.; Smith, D.W.; Wack, M.E.; Denys, G.A. (2002). Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy, 22, 395-399.
39. Kiffer, C.; Hsiung, A.; Oplustil, C.; Sampaio, J.; Sdagami, E.; Turner, P.; Mendes, C. (2005). Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz. J. Infect. Dis., 9, 216-224.
40. Kiffer, C.R.V.; Kuti, J.L.; Mendes, C.M.F.; Oplustil, C.P.; Amarante, J.B.; Biancalana, M.L.; Xavier, N.; Nicolau, D.P. A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian intensive care unit. Brazilian J. Infect. Dis., in press.
41. Kiffer, C.R.V.; Mendes, C.; Kuti, J.L.; Nicolau, D.P. (2004). Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn. Microbiol. Infect. Dis., 49, 109-116.
42. Kuti, J.L.; Dandekar, P.K.; Nightingale, C.H.; Nicolau, D.P. (2003). Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol., 43, 1116-1123.
43. Kuti, J.L.; Moss, K.M.; Nicolau, D.P.; Knauft F.R. (2004). Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy, 24: 1641-1645.
44. Kuti, J.L.; Nicolau, D.P. (2005). Making the most of surveillance studies: summary of the OPTAMA Program. Diagn. Microbiol. Infect. Dis., 53, 281-287.
45. Lacy, M.K.; Lu, W.; Xu, X.; Tessier, P.R.; Nicolau, D.P.; Quintiliani, R.; Nightingale, C.H. (1999). Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother., 43, 672-677.
46. Li, C.; Du, X.; Kuti, J.L.; Nicolau, D.P. (2005). Clinical pharmacodynamics of meropenem in adult patients with lower respiratory tract infections [abstract A-1147]. In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Am. Soc. Microbiol., Washington D.C., p.20.
47. Li, J.; Turnidge, J.; Milne, R.; Nation, R.L.; Coulthard, K. (2001). In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother., 45, 781-785.
48. Linares, J. (2001). The VISA/GISA problem: therapeutic implications. Clin Microbiol. Infect., 7 (Suppl 4), 8-15.
49. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Am. Soc. Microbiol., Washington, DC, p.446.
50. Lodise, T.P.; Preston, S.; Bhargava, V.; Bryskier, A.; Nusrat, R.; Chapel, S.; Rangaraju, M.; Drusano, G.L. (2005). Pharmacodynamics of an 800-mg dose of telitromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn. Microbiol. Infect. Dis., 52, 45-52.
51. Louie, A.; Kaw, P.; Liu, W.; Jumbe, N.; Miller, M.H.; Drusano, G.L. (2001). Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents. Chemother., 45, 845-851.
52. Ludwig, E.; Konkoly-Thege, M.; Kuti, J.L.; Nicolau, D.P. (2006). Optimizing antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian Hospitals. Int. J. Antimicrob. Agents., 28, 433-438.
53. Maglio, D.; Ong, C.; Banevicius, M.A.; Nightingale, C.H.; Nicolau, D.P. (2004). Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula. Antimicrob. Agents Chemother., 48, 1941-1947.
54. Mattoes, H.M.; Kuti, J.L.; Drusano, G.L.; Nicolau, D.P. (2004). Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Therapeutics, 26, 1187-1198.
55. Meagher, A.; Passarell, J.; Cirincione, B.; Van Wart, S.; Liolios, K.; Babinchak, T.; Ellis-Grosse, E.J.; Ambrose, P.G. (2005). Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections [abstract P1184]. Clin. Microbiol. Infect., 11 (Suppl 2), 373-374.
56. Mendes, C.M.F.; Marin, M.E.; Quinones, F.; Sifuentes-Osornio, J.; Siller, C.C.; Castanheira, M.; Zoccoli, C.M.; Lopez, H.; Sucari, A.; Rossi, F.; Angulo, G.B.; Segura, A.J.; Starling, C.; Mimica, I.; Felmingham, D. (2003). Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000). Braz. J. Infect. Dis., 7, 44-61.
57. Moise, P.A.; Forrest, A. Bhavnani, S.M.; Birmingham, M.C.; Schentag, J.J. (2000). Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health-Syst. Pharm., 57, 84-89.
58. Moise-Broder, P.A.; Forrest, A.; Birmingham, M.C.; Schentag, J.J. (2004). Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet., 43, 925-942.
59. Moore, R.D.; Lietman, P.S.; Smith, C.R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis., 155, 93-99.
60. Moore, R.D.; Smith, C.R.; Lietman, P.S. (1984). The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J. Infect. Dis., 149, 443-448.
61. Mutnick, A.H.; Biedenbach, D.J.; Jones, R.N. (2003). Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis., 46, 63-68.
62. Nicolau, D.P.; Freeman, C.D.; Belliveau, P.P.; Nightingale, C.H.; Ross, J.W.; Quintiliani, R. (1995). Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother., 39, 650-655.
63. th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C., p.22.
64. Preston, S.L.; Drusano, G.L.; Berman, A.L.; Fowler, C.L.; Chow, A.T.; Dornseif, B.; Reichl, V.; Natarajan, J.; Corrado, M. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA, 279, 125-129.
65. Rybak, M.J. (2006). The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis., 42, S35-S39.
66. Sader, H.S.; Castanheira, M.; Mendes, R.E.; Toleman, M.; Walsh, T.R.; Jones, R.N. (2005). Dissemination and diversity of metallo-β-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int. J. Antimicrob. Agents, 25, 57-61.
67. Sader, H.S.; Jones, R.N.; Andrade-Baiocchi, S.; Biedenbach, D.J. (2003). Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin America medical centers. Diagn. Microbiol. Infect. Dis., 44, 273-280.
68. Sader, H.S.; Jones R.N.; Stilwell, M.G.; Dowzicky, M.J.; Fritsche, T.R. (2005). Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis., 52, 181-186.
69. Sakoulas, G.; Moise-Broder, P.A.; Schentag, J.J.; Forrest, A.; Moellering, R.C.; Eliopoulos, G.M. (2004). Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol., 42, 2398-2402.
70. Sprandel, K.A.; Drusano, G.L.; Hecht, D.W.; Rotschafer, J.C.; Danziger, L.H.; Rodvold, K.A. (2006). Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn. Microbiol. Infect. Dis., 55, 303-309.
71. Stelling, J.M.; Travers, K.; Jones, R.N.; Turner, P.J.; O'Brien, T.F.; Levy, S.B. (2005). Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg. Infect. Dis., 11, 873-882.
72. Tam, V.H.; Louie, A.; Deziel, M.R.; Liu, W.; Leary, R.; Drusano, G.L. (2005). Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis., 192, 420-428.
73. Tam, V.H.; Louie, A.; Lomaestro, B., Drusano, G.L. (2003). Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy, 23, 291-295.
74. Tam, V.H.; McKinnon, P.S.; Akins, R.L.; Rybak, M.J.; Drusano, G.L. (2002). Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother., 50, 425-428.
75. Tam, V.H.; Schilling, A.N.; Vo, G.; Kabbara, S.; Kwa, A.L.; Wiederhold, N.P.; Lewis, R.E. (2005). Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 49, 3624-3630.
76. Tessier, P.R.; Mattoes, H.M.; Dandekar, P.K.; Nightingale, C.H.; Nicolau, D.P. (2005). Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother., 49, 188-194.
77. Tognim, M.C.; Andrade, S.S.; Silbert, S.; Gales, A.C.; Jones, R.N.; Sader, H.S. (2004). Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multidrug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int. J. Infect. Dis., 8, 284-291.
78. Turnidge, J.D. (1998). The pharmacodynamics of β-lactams. Clin. Infect. Dis., 27, 10-22.
79. Unal, S.; Garcia-Rodriquez, J.A. (2005). Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis., 53, 265-271.
80. Van Ogtrop, M.L.; Andes, D.; Stamstad, T.J.; Conklin, B.; Weiss, W.J.; Craig, W.A.; Vesga, O. (2000). In vivo pharmacodynamic activities of two glycylcyclines (GAR-936) and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother., 44, 943-949.
81. Villegas, M.V.; Correa, A.; Perez, F.; Miranda, M.C.; Zuluaga, T.; Quinn, J.P. (2004). Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn. Microbiol. Infect. Dis., 49, 217-222.
82. Wallace, A.W.; Jones, M.; Bertino, J.S. (2002). Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy, 22, 1077-1083.
83. Wright, D.H.; Brown, G.H.; Peterson, M.L.; Rotschafer, J.C. (2000). Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother., 46, 669-683.